日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer

帕博西尼联合芳香化酶抑制剂治疗HR+/HER2-骨转移性乳腺癌的真实世界疗效

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2026.104744
Brufsky, Adam; Layman, Rachel M; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Cohen, Aaron B; Estevez, Melissa; Cottu, Paul; Curigliano, Giuseppe; Rugo, Hope S
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice

美国常规临床实践中，CDK4/6抑制剂联合芳香化酶抑制剂治疗HR+/HER2-转移性乳腺癌患者的真实世界无进展生存期2（PFS2）和肿瘤反应

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2026.104780
Rugo, Hope S; Brufsky, Adam; Layman, Rachel M; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Cohen, Aaron B; Estevez, Melissa; Lynce, Filipa; Cottu, Paul; Thill, Marc; Curigliano, Giuseppe
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting

在美国真实世界环境中，CDK4/6抑制剂联合芳香化酶抑制剂治疗HR+/HER2-转移性乳腺癌患者的总生存期比较

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.104103
Rugo, H S; Layman, R M; Lynce, F; Liu, X; Li, B; McRoy, L; Cohen, A B; Estevez, M; Curigliano, G; Brufsky, A
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting

回复关于“在美国真实世界环境中，CDK4/6抑制剂联合芳香化酶抑制剂治疗HR+/HER2-转移性乳腺癌的总体生存率比较”的来信

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105297
Rugo, H S; Layman, R M; Lynce, F; Liu, X; Li, B; McRoy, L; Cohen, A B; Estevez, M; Curigliano, G; Brufsky, A
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice

美国常规临床实践中，CDK4/6抑制剂联合芳香化酶抑制剂治疗HR阳性/HER2阴性转移性乳腺癌的真实世界无进展生存期

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105570
Rugo, H S; Layman, R M; Lynce, F; Liu, X; Li, B; McRoy, L; Cohen, A B; Estevez, M; Curigliano, G; Brufsky, A
CDK4
肿瘤
HER2
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis

真实世界中帕博西尼剂量调整对HR+/HER2-转移性乳腺癌患者临床结局的影响：一项基于Flatiron Health数据库的分析

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2025.104448
Layman, Rachel M; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Brufsky, Adam
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods

帕博西尼联合芳香化酶抑制剂治疗居住在弱势社区的 HR+/HER2- 转移性乳腺癌患者的真实世界疗效

期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-025-00786-z
Lynce, Filipa; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Chen, Connie; Liu, Raymond; Rugo, Hope S
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Using Large Language Models to Assess Burnout Among Health Care Workers in the Context of COVID-19 Vaccine Decisions and Health Beliefs: Retrospective Cohort Study

利用大型语言模型评估医护人员在新冠疫苗决策和健康信念背景下的职业倦怠：回顾性队列研究

期刊:JMIR Nursing
影响因子:4
doi:10.2196/73672
Omranian, Samaneh; He, Lu; Talsma, AkkeNeel; Scoglio, Arielle A J; McRoy, Susan; Rich-Edwards, Janet W
微生物学
新冠
发表日期：2025
文献求助 收藏

De novo missense variants in CHTF18: The potential to expand the clinical spectrum of cohesinopathies

CHTF18 中的新生错义变异：可能扩大黏连蛋白病的临床谱

期刊:HGG Advances
影响因子:3.6
doi:10.1016/j.xhgg.2025.100485
Aref-Eshghi, Erfan; Wentzensen, Ingrid M; Ben-Omran, Tawfeg; Bux, Reem Ibrahim; Gold, Nina B; McRoy, Erin; Nguyen, Hoanh; O'Grady, Lauren; Tu, Shao Ching; Chen, Yanmin; Folk, Leandra; McGivern, Bobbi
发表日期：2025
文献求助 收藏

Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summary

帕博西尼联合芳香化酶抑制剂治疗已扩散至肺或肝的激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌患者：简明语言摘要

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2481017
Brufsky, Adam; Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Chen, Connie; Layman, Rachel M; Rugo, Hope S
肿瘤
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏